ArticleNature2025
mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.Nature reviews. Drug discovery · 2026Review
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Intestinal epithelial SETD2 maintains gut microbial homeostasis to attenuate colitis.Clinical and translational medicine · 2026Article
- Inflammatory gut-liver crosstalk: mechanisms and therapeutic targets.Experimental & molecular medicine · 2026Review
- Gut-liver axis molecular mechanisms in alcohol-associated liver disease.Alcohol (Fayetteville, N.Y.) · 2026Review
- Regulation of immune tolerance in hepatocellular carcinoma by liver diseases: a review.Infectious agents and cancer · 2026Review
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Parallel regulation of goblet cell-associated antigen passages by reduced microbial sensing and mAChR4 signaling in Muc2 deficiency prevents ethanol-induced liver injury.Hepatology (Baltimore, Md.) · 2026Article
- Intestinal GAPs: neuro-epithelial-immune modules for liver protection.Cell research · 2026Article
- Goblet-cell muscarinic signaling at the gut barrier: A therapeutic checkpoint/target in alcohol-related liver disease.JHEP reports : innovation in hepatology · 2026Article
- The "Immune Rebellion" from the Intestines to the Liver: A Vicious Cycle That Causes the Liver to Collapse.Metabolites · 2026Review
- Restoration of ethanol-induced Bifidobacterium pseudocatenulatum depletion ameliorates alcohol-associated liver disease.NPJ biofilms and microbiomes · 2026Article
- Targeting gut immunity as a therapy for steatotic liver disease.eGastroenterology · 2026Article
- Oxidative Stress in Liver Metabolic Dysfunction and Diseases, with a Focus on Hepatogenic Diabetes: Effect of Alcohol Consumption.Antioxidants (Basel, Switzerland) · 2025Review
- Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.Pharmacological reviews · 2025Review
- Metabolic dysfunction and alcohol-associated liver disease (MetALD).eGastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Cristina Llorente *Department of Medicine, University of California San Diego, La Jolla, CA, USA. allorenteizquierdo@health.ucsd.edu.ORCID 0000-0001-8135-9186
Fernanda Raya Tonetti *Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Ryan BruellmanDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-4450-5508
Rocío BreaDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Nuria PellDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Phillipp HartmannDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Luca MaccioniInstitute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology, UC Louvain, Université Catholique de Louvain, Brussels, Belgium.
Hui HanDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Noemí CabréDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Junlai LiuLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego, La Jolla, CA, USA.
Alvaro EguileorDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-0302-6762
Marcos F FondevilaDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Abraham S MeijnikmanDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-6015-4656
Cynthia L HsuDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-2604-1340
Ameera AlghafriDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Rongrong ZhouDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Bei GaoDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Yi DuanDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Peng ZhangLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-0469-7151
Mark A FebbraioMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-9296-4418
Koji TaniguchiLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego, La Jolla, CA, USA.
Rodney D NewberryDepartment of Internal Medicine, Washington University School of Medicine, St Louis, MI, USA.ORCID 0000-0002-4152-5191
Derrick E FoutsJ. Craig Venter Institute, Rockville, MD, USA.ORCID 0000-0003-4323-7668
David A BrennerDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Peter StärkelInstitute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology, UC Louvain, Université Catholique de Louvain, Brussels, Belgium.ORCID 0000-0003-2938-4442
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego, La Jolla, CA, USA. karinoffice@ucsd.edu.ORCID 0000-0002-2758-6473
Bernd SchnablDepartment of Medicine, University of California San Diego, La Jolla, CA, USA. beschnabl@ucsd.edu.ORCID 0000-0002-6281-825X
Funding
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HIDEKAZU TSUKAMOTO · 1999 to 2026
$45.8MUC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MNF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of InflammationR37AI043477 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2018 to 2026
$6.0MResource-based Center for the study of the joint microenvironment in rheumatology (Overall Application)P30AR073761 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CORR, MARY P · 2018 to 2022
$3.9MThe Role of the Intestinal Mycobiome in Alcoholic Liver DiseaseR01AA024726 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2018 to 2026
$3.9MImmunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitorsU01AA027681 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EL-KHOUEIRY, ANTHONY BOUTROS, KARIN, MICHAEL · 2018 to 2022
$3.6MHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitorsR01CA234128 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2019 to 2023
$2.7MMicrobiome and Intestinal Innate Immune Response in Alcoholic Liver DiseaseR37AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2021 to 2026
$2.5MGoblet cells and intestinal immune response in alcohol-associated liver diseaseR01AA029106 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ana Cristina Llorente Izquierdo · 2022 to 2026
$2.3MDeveloping Diverse Physician-Investigator Leaders for the Future of Child HealthK12HD105271 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Gabriel G Haddad · 2021 to 2026
$1.8MMicrobiome as therapeutic target in alcoholic hepatitisU01AA026939 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FOUTS, DERRICK E, SCHNABL, BERND G. · 2018 to 2022
$1.7MBLRD VA I01 BX004594NCATS NIH HHS KL2 TR001444NCI NIH HHS R01 CA234128NIAAA NIH HHS K99 AA031328NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA024726NIAAA NIH HHS R01 AA029106NIAAA NIH HHS R21 AA030654NIAAA NIH HHS R37 AA020703NIAAA NIH HHS U01 AA026939NIAAA NIH HHS U01 AA027681NIAID NIH HHS R37 AI043477NIAMS NIH HHS P30 AR073761NICHD NIH HHS K12 HD105271NIDDK NIH HHS P30 DK120515
Abstract
Alcohol-use disorder and alcohol-associated liver disease (ALD) are major causes of death and liver transplantation
Indexed as
Goblet CellsImmunity, InnateLiver Diseases, AlcoholicAlcoholismAnimalsBacterial TranslocationDown-RegulationFemaleHumansInterleukin-22InterleukinsIntestine, SmallLiverMaleMiceMice, Inbred C57BLInterleukin-22InterleukinsPancreatitis-Associated ProteinsReg3g protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.